Literature DB >> 2205095

Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells.

C Richard1, M A Cuadrado, M Prieto, J Batlle, M F López Fernández, M L Rodriguez Salazar, C Bello, M Recio, T Santoro, M T Gomez Casares.   

Abstract

A case of acquired von Willebrand disease (AvWD) associated with an IgA lambda multiple myeloma is reported. No form of inhibitor could be detected. SDS-agarose gel electrophoresis patterns of von Willebrand factor (vWF) both in plasma and platelet lysates were normal but a decrease in all-sized multimers with a type IA pattern was seen. After 1-deamino-8-D arginine vasopressin (DDAVP) infusion, vWF multimers larger than those seen in the resting state appeared in patient plasma, which were progressively cleared. Indirect immunofluorescence studies with a monoclonal antibody to vWF showed that vWF was selectively absorbed into myelomatous cells. This is the first case of AvWD associated with multiple myeloma resulting from the selective absorption of vWF into abnormal plasma cells. This feature established a new pathophysiological mechanism of AvWD in multiple myeloma and probably in other lymphoproliferative diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2205095     DOI: 10.1002/ajh.2830350210

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

Review 1.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

2.  Isolated coagulopathy without classic CRAB symptoms as the initial manifestation of multiple myeloma: A case report.

Authors:  Ya Zhang; Fang Xu; Jing-Jing Wen; Lin Shi; Qiao-Lin Zhou
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

Review 3.  Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Authors:  Hiroshi Mohri
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

4.  Acquired von Willebrand's disease.

Authors:  B J Hennessy; B White; M Byrne; O P Smith
Journal:  Ir J Med Sci       Date:  1998 Apr-Jun       Impact factor: 1.568

5.  Acquired von Willebrand Syndrome in IgM Monoclonal Gammopathy as the Presentation of Lymphoplasmacytic Lymphoma.

Authors:  Zachary Wolfe; Bradley Lash
Journal:  Case Rep Hematol       Date:  2017-05-29

6.  Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma.

Authors:  Dominique Maas; Britta Laros-van Gorkom; Sanne Gianotten; Marjan Cruijsen; Waander van Heerde; Marten Nijziel
Journal:  Case Rep Hematol       Date:  2018-01-30

Review 7.  Acquired von Willebrand syndrome: focused for hematologists.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2020-06-18       Impact factor: 9.941

8.  Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy.

Authors:  Allen Green; Yu-Min P Shen; Andrew T Nelson; Ravi Sarode; Ibrahim F Ibrahim; Jing Cao; Sajjad Afraz; Sean G Yates
Journal:  Ann Hematol       Date:  2022-10-04       Impact factor: 4.030

9.  Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy Leading to Acute Kidney Injury: Revisiting a Very Rare Entity.

Authors:  Savneek Chugh; Asim Kichloo; Firas Jafri; Liga Yusvirazi; Robert Lerner
Journal:  J Investig Med High Impact Case Rep       Date:  2017-09-22

Review 10.  The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer.

Authors:  Chanukya K Colonne; Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Healthcare (Basel)       Date:  2022-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.